A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C] ASN002 Following a Single Oral Dose in Healthy Male Subjects
Latest Information Update: 27 Feb 2023
At a glance
- Drugs Gusacitinib (Primary)
- Indications Atopic dermatitis; Chronic lymphocytic leukaemia; Myelofibrosis; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Solid tumours
- Focus Pharmacokinetics
- Sponsors Asana BioSciences
Most Recent Events
- 31 Oct 2018 Status changed from not yet recruiting to completed.
- 28 Aug 2018 New trial record